**Specifications TableSubject**Psychiatry and Mental Health; Endocrinology, Diabetes and Metabolism**Specific subject area**Management of antipsychotic-induced hyperprolactinaemia**Type of data**Table\
Figure\
Box\
Code\
List**How data were acquired**Four electronic bibliographic databases were searched: PubMed, Scopus, PsycINFO and ClinicalTrials.gov. The following search strategy was used: prolactin AND (switch\* OR aripiprazole OR bromocriptine OR cabergoline OR \"dopamine agonist\" OR metformin) AND (schizophrenia OR schizoaffective OR psychosis OR psychotic OR bipolar\*). Language was restricted to those articles written in English, Spanish, German or French. Studies published between January 1980 and March 2020 were considered for inclusion. The systematic review contained trials including patients with psychotic disorders (schizophrenia, schizoaffective disorder, bipolar disorder, brief psychotic disorder, delusional disorder, or psychotic disorder not otherwise specified) who had hyperprolactinaemia. Clinical trials and observational studies were included if they assessed the efficacy of any of the following four therapeutic options for lowering prolactin (switching antipsychotic treatment, adding aripiprazole, adding other dopamine agonists \[e.g., cabergoline, bromocriptine\], or adding metformin) and had information on prolactin levels at baseline and after follow-up that would allow the calculation of the effect size for the reduction in prolactin concentrations. Exclusion criteria were case reports or studies of less than 5 cases, and studies assessing prolactin changes in psychotic patients for whom the main reason for the therapeutic strategy was not hyperprolactinaemia (e.g., switching in treatment-resistant patients).\
Although the systematic review included clinical trials and observational studies, only randomized clinical trials (RCTs) were considered for conducting a meta-analysis. The primary outcome was defined as the reduction in prolactin concentrations. The software R and the package metafor were used for conducting the meta-analysis on the primary outcome (reduction in prolactin levels). Hedges g' was used as the effect size for prolactin reduction. An additional meta-analysis for withdrawal rates in placebo-controlled RCTs was performed with MedCalc (version 18.11).**Data format**Raw data of prolactin concentrations and withdrawal rates are included in the original article\
Additional raw data on the current article\
Analyzed\
Filtered\
Methodological explanations**Parameters for data collection**We aimed to identify clinical trials and observational studies considering four therapeutic options for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: switching antipsychotic treatment, adding aripiprazole, adding other dopamine agonists (e.g., cabergoline, bromocriptine), or adding metformin.**Description of data collection**The PRISMA group guidelines were followed. A standardised, pre-piloted form was used to extract data from the included studies for assessment of the study quality and evidence synthesis. Two review authors extracted data independently, and discrepancies were identified and resolved through discussion (with two additional authors when necessary). Missing data were requested from study authors. In a few cases in which data were only available in figures (either as individual concentrations or aggregated with mean and standard deviation), we extracted this information from figures using the procedure explained in [Box 1](#tbl0011){ref-type="table"}.**Data source location**Institution: Parc Taulí Hospital Universitari\
City: Sabadell\
Country: Spain**Data accessibility**With the article\
**Related research article**Javier Labad, Itziar Montalvo, Alexandre González-Rodríguez, Clemente García-Rizo, Benedicto Crespo-Facorro, José Antonio Monreal, Diego Palao. Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: a systematic review and meta-analysis. Schizophrenia Research. 2020.\

**Value of the data**These data describe the scientific evidence published between 1980 and 2020 on four pharmacologic strategies (switching antipsychotic treatment, adding aripiprazole, adding other dopamine agonists \[e.g., cabergoline, bromocriptine\], or adding metformin) for reducing prolactin concentrations in people with psychotic disorders and hyperprolactinaemia.The data will be useful for psychiatrists, endocrinologists and other health professionals treating patients with psychotic disorders who may develop hyperprolactinaemia.The data is useful for being considered in future guidelines for treating hyperprolactinaemia in patients with psychotic disorders who usually require long-term antipsychotic treatment that might increase prolactin levels.

Data description {#sec0001}
================

The data presented in this paper describe supplementary material to the original article [@bib0001]. Data will be described in the same order of appearance in the text of the article [@bib0001].

[Table 1](#tbl0001){ref-type="table"} represents the PICO scheme of the systematic review.Table 1PICO scheme of the systematic review.Table 1Patient, population or ProblemInterventionComparisonOutcome***What are the characteristics of the patients or population?**What interventions are we considering?**What is the alternative to the intervention?**What are the relevant outcomes?***Psychotic disorders, including schizophrenia, bipolar disorder and schizophrenia-spectrum psychotic disorders with hyperprolactinaemia.Four strategies for lowering prolactin:\
Switching antipsychotics\
Adding aripiprazole\
Adding other dopamine agonists (e.g., cabergoline, bromocriptine)\
Adding metforminPlacebo or maintaining antipsychotic treatment (randomized clinical trials with comparison arms will be included in the meta-analysis).\
Uncontrolled studies (with comparator) will be included in the systematic review if there is information regarding changes in prolactin with the strategy.Reduction in prolactin plasma concentrations.

[Table 2](#tbl0002){ref-type="table"} comprises the PRISMA Checklist and references all items and pages in the original article.Table 2PRISMA Checklist of the systematic review.Table 2Section/topic\#Checklist itemReported on page \#TitleTitle1Identify the report as a systematic review, meta-analysis, or both.1AbstractStructured summary2Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.1IntroductionRationale3Describe the rationale for the review in the context of what is already known.1--2Objectives4Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).2\
[Table 1](#tbl0001){ref-type="table"} DIBMethodsProtocol and registration5Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.2Eligibility criteria6Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.2Information sources7Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.2Search8Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.2Study selection9State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).2\
[Fig. 1](#fig0001){ref-type="fig"} DIBData collection process10Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.2Data items11List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.2Risk of bias in individual studies12Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.3Summary measures13State the principal summary measures (e.g., risk ratio, difference in means).3Synthesis of results14Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2^) for each meta-analysis.3Section/topic\#Checklist itemReported on page \#Risk of bias across studies15Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).3Additional analyses16Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.3RESULTSStudy selection17Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.[Fig. 1](#fig0001){ref-type="fig"} DIBStudy characteristics18For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.3, List 1 DIB, Tables OARisk of bias within studies19Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).4\
[Table 9](#tbl0009){ref-type="table"} DIBResults of individual studies20For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.4, Tables & Figure OASynthesis of results21Present results of each meta-analysis done, including confidence intervals and measures of consistency.4Risk of bias across studies22Present results of any assessment of risk of bias across studies (see Item 15).[Table 9](#tbl0009){ref-type="table"} DIBAdditional analysis23Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression \[see Item 16\]).4DiscussionSummary of evidence24Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).6Limitations25Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).7--8Conclusions26Provide a general interpretation of the results in the context of other evidence, and implications for future research.8FundingFunding27Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.Role funding source OA[^1]

[Fig. 1](#fig0001){ref-type="fig"} represents the flow diagram of included studies.Fig. 1Flow diagram of included studies.Fig 1

[Box 1](#tbl0011){ref-type="table"} explains the procedure for obtaining prolactin concentrations from figures when information on the text or tables was not available.

Code 1 indicates the R code used for calculating the foster plot and funnel plot of the meta-analysis dealing with the primary outcome (prolactin reduction).

Code 2 indicates the R code used for calculating the foster plot and funnel plot of the sensitivity meta-analysis including only placebo-controlled RCTs dealing with the primary outcome (prolactin reduction).

List 1 describes all the studies included in the systematic review.

[Tables 3](#tbl0003){ref-type="table"}, [4](#tbl0004){ref-type="table"} and [5](#tbl0005){ref-type="table"} show raw data on selected articles dealing with socio-demographic and clinical characteristics ([Table 3:](#tbl0003){ref-type="table"} Switching studies; [Table 4:](#tbl0004){ref-type="table"} Aripiprazole addition studies; [Table 5:](#tbl0005){ref-type="table"} Studies focused on the addition of other dopamine agonists).Table 3Socio-demographic and clinical characteristics of the samples of studies dealing with switching antipsychotic treatment to lower prolactin.Table 3ReferenceCountryEthnicityAge (years)\
Mean (SD)Duration of illness (years)\
Mean (SD)Duration of treatment with PRL-elevating antipsychoticSubstance useSymptoms\
(baseline visit)**Switch to aripiprazole**Yoon et al., 2016KoreaNR34.7 (8.0)8.4 (7.4)\>1 monthsubstance abuse or dependence were excludedstable over 2 months (no changes in CGI-S)Chen et al. 2011ChinaNR48.3 (8.2)17.9 (9.1)NRNRCGI-S: 5.1 (0.9)Lu et al., 2008China (Taiwan)NR31.7 (9.3)5.5 (5.4)NRNRCGI-S: 3.4 (0.5)\
PANSS total: 53.4 (7.7)Lee et al., 2006KoreaNR35.0 (7.4)2.6 (2.3)\>2 months\
6.1 (1.8)NRPANSS total: 45.0 (9.0)**Switch to olanzapine**Kinon et al., 2006USA48.1% caucasian\
40.7% african\
7.4% asian\
3.7% hispanic40.0 (10.7)14.3 (7.9)NR[†](#tb3fn1){ref-type="table-fn"}Alcohol or substance abuse were excludedCGI-S: 3.4 (0.7)\
PANSS total: 57.5 (16.0)**Switch to quetiapine**Nakajima et al., 2005JapanNR55.0 (12.0)26.6 (11.6)\>1 monthNRPANSS positive: 12.8 (4.7)\
PANSS negative: 18.7 (7.0)\
PANSS general psychopathology: 41.2 (9.9)Takahashi et al., 2003JapanNR25.7 (5.1)NR14.6 (5.3)NRBPRS: 42.4 (7.6)**Switch to paliperidone**Montalvo et al., 2013SpainNR26.6 (5.9)\<5 years (early psychosis)\>6 monthsNRPANSS positive: 10.2 (3.5)\
PANSS negative: 14.2 (4.4)\
PANSS general psychopathology: 25.5 (4.5)**Switch to blonanserin**Kawabe et al., 2013Japan and South KoreaNR53.9 (8.4)31.7 (9.4)NRNRBPRS: 47.8 (8.4)[^2][^3]Table 4Socio-demographic and clinical characteristics of the samples of studies dealing with the addition of aripiprazole to lower prolactin.Table 4ReferenceCountryEthnicityAge (years) Mean (SD)Duration of illness (years) Mean (SD)Duration of treatment with PRL-elevating antipsychoticSubstance useSymptoms (baseline visit)Kelly et al., 2018USA66% african american 33% white37.8 (8.9)NR^†^\>2 monthsSubstance abuse was an exclusion criterionClinical stability (psychiatrist consideration) was an inclusion criterion\
BPRS: 35.4 (10.0)\
CGI-S: 3.8 (0.9)Fujioi et al., 2017JapanNR41.3 (8.0)15.2 (8.3)\>2 monthsNRBPRS: 44.1 (12.5)\
CGI-S: 4.0 (0.9)Yoon et al., 2016KoreaNR35.8 (7.1)11.1 (7.3)\>1 monthSubstance abuse or dependence was an exclusion criterionClinically stable over 2 months (no changes in CGI-S)Qiaio et al., 2016ChinaNR34.1 (7.0)14.3 (20.9)1 monthSubstance dependence was an exclusion criterionPANSS total between 60 and 120 (inclusion criterion)\
PANSS total: 66.8 (14.2)Chen et al., 2015ChinaNR34.4 (8.8)10.38 (7.0)\>6 weeks\
9.2 (3.3) weeksSubstance use was an exclusion criterionClinical stability (PANSS\<70) was an inclusion criterionZhao et al., 2015ChinaNR28.9 (7.8)4.2 (4.2) months\>2 monthsSubstance use (including alcohol consumption) was an exclusion criterionStable psychiatric condition was an inclusion criterion\
PANSS total: 57.5 (13.5)Ziadi Trives et al., 2013Spain100% white42.0 (11.4)NR\>6 monthsSubstance use was an exclusion criterionClinical stability (no changes in treatment or ER visits in the previous 6 months) was an inclusion criterion\
CGI-S: 3.7 (1.3)Van Kooten et al., 2011Netherlands83.3% white\
16.6% asian47.6 (13.6)21.3 (12.2)\>12 months\
43.2 (36) monthsNRNRYasui-Furukori et al., 2010Japan44.5 (9.5)18.9 (13.4)\>3 monthsNRPANSS total: 72.9 (25.0)\
PANSS positive: 11.9 (3.5)\
PANSS negative: 19.6 (5.2)Chen et al., 2010China (Taiwan)NR37.4 (9.0)12.6 (9.1)\>1 month\
9.3 (10.4)NRPANSS total: 90.2 (57.2)Chen et al., 2009ChinaNRNRNRNRNRNRShim et al., 2007KoreaNR38.2 (5.3)15.3 (6.1)\>3 monthsSubstance use was an exclusion criterionClinical stability was an inclusion criterion\
BPRS: 45--5 (12.3)\
CGI-S: 4.2 (0.9)[^4]Table 5Socio-demographic and clinical characteristics of the samples of studies dealing with the addition of dopamine agonists to lower prolactin.Table 5ReferenceCountryEthnicityAge (years)\
Mean (SD)Duration of illness (years)\
Mean (SD)Duration of treatment with PRL-elevating antipsychoticSubstance useSymptoms\
(baseline visit)**Cabergoline addition**Kalkavoura et al., 2013GreeceNR43.6 (9.8)21.8 (11.9)NR[†](#tb5fn1){ref-type="table-fn"}Alcohol abuse was an exclusion criterion.PANSS total: 62.9 (2.5)Coronas et al., 2012SpainNR31.2 (5.0)NRNRNRClinical stable before starting cabergoline\
BPRS: 21.7 (4.9)Cavallaro et al., 2004ItalyNR33.7 (5.6)NR\>6 monthsNRNR**Bromocriptine addition**Yuan et al., 2008ChinaNR31.1 (7.9)3.2 (3.5)\>6 monthsNRNRBliesener et al., 2004GermanyNR20--45 yearsNR\>4 monthsNRNR**Terguride addition**Hashimoto et al., 2014JapanNR42.9 (10.6)15.0 (5.8)26.7 (11.9) monthsNRNR[^5][^6]

[Tables 6](#tbl0006){ref-type="table"}, [7](#tbl0007){ref-type="table"} and [8](#tbl0008){ref-type="table"} show raw data on diagnostic criteria for psychotic disorders and exclusion criteria related to reproductive or medical conditions that can alter prolactin levels ([Table 6:](#tbl0006){ref-type="table"} Switching studies; [Table 7:](#tbl0007){ref-type="table"} Aripiprazole addition studies; [Table 8:](#tbl0008){ref-type="table"} Studies focused on the addition of other dopamine agonists).Table 6Diagnostic criteria for psychotic disorders and exclusion criteria for conditions that can alter prolactin levels of studies dealing with switching antipsychotics to lower prolactin.Table 6ReferenceDiagnostic criteria for psychotic disordersExclusion criteria (reproductive or medical conditions that can alter prolactin levels)[†](#tb6fn1){ref-type="table-fn"}**Switch to aripiprazole**Yoon et al., 2016DSM-IVpregnant or lactating, other diseases that can elevate the prolactin level such as Cushing disease, primary hypothyroidism, liver cirrhosis, renal failure, or prolactinomaChen et al. 2011NRNRLu et al., 2008DSM-IVendocrine disease, gynecological problems, or other major medical illnesses .Lee et al., 2006DSM-IVmedical maladies (e.g., thyroid or gynecological diseases)**Switch to olanzapine**Kinon et al., 2006DSM-IVsuspicious MRI scan, pregnant or nursing, bilateral oophorectomy or hysterectomy during or preceding their peri‑menopause, treatment with reproductive hormone therapy, serious unstable illnesses (hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic, or hematologic disease), seizures, current agranulocytosis, any other medication with primarily central nervous system activity or that would elevate prolactin**Switch to quetiapine**Nakajima et al., 2005DSM-IVNRTakahashi et al., 2003DSM-IVNR**Switch to paliperidone**Montalvo et al., 2013NRNR**Switch to blonanserin**Kawabe et al., 2013DSM-IVNR[^7][^8]Table 7Diagnostic criteria for psychotic disorders and exclusion criteria for conditions that can alter prolactin levels of all studies dealing with the addition of aripiprazole to lower prolactin.Table 7ReferenceDiagnostic criteria for psychotic disordersExclusion criteria (reproductive or medical conditions that can alter prolactin levels)[†](#tb7fn1){ref-type="table-fn"}**Aripiprazole addition**Kelly et al., 2018DSM-IVpostmenopause, pregnancy or current post-pregnancy lactation, history of a pituitary tumor (microadenoma, macroadenoma, neoplasm) or Cushing disease, medications that may affect prolactin or cause sexual dysfunction through dopaminergic effects (eg, metoclopramide, methyldopa, reserpine, amoxapine, droperidol, prochlorperazine, promethazine, bromocriptine, and cabergoline)Fujioi et al., 2017DSM-IVmenopause, pregnancy, or breast-feedingYoon et al., 2016DSM-IVpregnant or lactating; other diseases that can elevate the prolactin level such as Cushing disease, primary hypothyroidism, liver cirrhosis, renal failure, or prolactinomaQiaio et al., 2016DSM-IVneurologic disorder, severe head trauma, or any unstable medical conditionChen et al., 2015DSM-IVsignificant medical illnesses, such as liver or renal dysfunction, cardiovascular disease, organic brain disorder; pregnant or lactating; other medications than risperidone, anticholinergics or benzodiazepines, such as other antipsychotics, antidepressants, or mood stabilizers etc., which may alter prolactin levelsZhao et al., 2015DSM-IVsignificant illnesses including severe cardiovascular, hepatic, or renal disease; history of immunosuppression; current or recent radiation or chemotherapy treatment for cancer; pregnancy or breastfeeding; other conditions (e.g., thyroid or gynecological diseases) that could affect serum prolactin levelsZiadi Trives et al., 2013NRintercurrent illness(es) that affect sexual function; other antipsychotics than risperidone; drugs that increase prolactin levels during the 6 months before their inclusion in the study (such as selective serotonin reuptake inhibitors), or any other treatment able to interfere with the adenohypophyseal system (oral contraceptives, tricyclic antidepressants, venlafaxine, mood stabilizers, antihypertensives, or H2 receptors' antagonists)Van Kooten et al., 2011DSM-IVtuberous sclerosis[‡](#tb7fn2){ref-type="table-fn"}Yasui-Furukori et al., 2010DSM-IVoral contraceptives or estrogen supplemental therapyChen et al., 2010DSM-IVNRChen et al., 2009DSM-IVNRShim et al., 2007DSM-IVmedical and/or neurological illness[^9][^10][^11]Table 8Diagnostic criteria for psychotic disorders and exclusion criteria for conditions that can alter prolactin levels of all studies dealing with the addition of dopamine agonists to lower prolactin.Table 8ReferenceDiagnostic criteria for psychotic disordersExclusion criteria (reproductive or medical conditions that can alter prolactin levels)[†](#tb8fn1){ref-type="table-fn"}**Cabergoline addition**Kalkavoura et al., 2013DSM-IVmedication implicated in the increase of PRL levels (tricyclic antidepressants, selective serotonin reuptake inhibitor, monoamine oxidase, a-methyldopa, estrogens, oral contraceptives), patients receiving medication implicated in sexual dysfunction (antihypertensives, diuretics, hormones, antifungoral therapy, Parkinson\'s disease), patients with hyperprolactinaemia due to pregnancy or breastfeeding, hypothyroidism, Cushing\'s syndrome, cirrhosis, renal failure, meningioma, craniopharyngioma, sarcoidosis, autoimmune disease, tumors of the hypothalamus, acromegalic dysplasia, prolactinoma, diabetes mellitusCoronas et al., 2012DSM-IVNRCavallaro et al., 2004DSM-IVNR**Bromocriptine addition**Yuan et al., 2008ICD-10NRBliesener et al., 2004NRNR[§](#tb8fn2){ref-type="table-fn"}**Terguride addition**Hashimoto et al., 2014DSM-IVNR[^12][^13][^14]

[Table 9](#tbl0009){ref-type="table"} report the risk of bias summary of all five randomized clinical trials evaluating the addition of aripiprazole for lowering prolactin.Table 9Risk of bias summary of all five randomized clinical trials evaluating the addition of aripiprazole for lowering prolactin.Table 9**Bias**Shim et al., 2007Chen et al., 2015Zhao et al., 2015Qiao et al., 2016Kelly et al., 2018Random sequence generationunclearlowunclearunclearlowAllocation concealmentunclearlowunclearunclearlowBlinding of participants and researchers[†](#tb9fn1){ref-type="table-fn"}lowlowlowlowlowBlinding of outcome assessment[†](#tb9fn1){ref-type="table-fn"}lowlowlowlowlowIncomplete outcome datalowlowlowlowlowSelective reportinglowlowlowlowlowOther biaslowlowlowlowlow**Quality of the clinical trial**fairgoodfairfairgood[^15]

[Fig. 2](#fig0002){ref-type="fig"} represents the funnel plot of the meta-analysis exploring changes in prolactin concentrations with the addition of aripiprazole. This figure has been generated with R.Fig. 2Funnel plot (meta-analysis of prolactin reduction).Fig 2

[Fig. 3](#fig0003){ref-type="fig"} represents the forest plot of the sensitivity meta-analysis including only placebo-controlled RCTs that studied the effects of adjunctive aripiprazole on prolactin reduction. This figure has been generated with R.Fig. 3Forest plot of the sensitivity meta-analysis of placebo-controlled RCTs studying adjunctive aripiprazole.Fig 3

[Fig. 4](#fig0004){ref-type="fig"} represents the funnel plot of the sensitivity meta-analysis including only placebo-controlled RCTs for prolactin reduction. This figure has been generated with R.Fig. 4Funnel plot of the sensitivity meta-analysis of placebo-controlled RCTs for prolactin reduction.Fig 4

[Fig. 5](#fig0005){ref-type="fig"} represents the forest plot of the meta-analysis of withdrawal rates in placebo-controlled RCTs studying adjunctive aripiprazole. This figure has been generated with MedCalc.Fig. 5Meta-analysis of withdrawal rates in placebo-controlled RCTs studying adjunctive aripiprazole.Fig 5

[Table 10](#tbl0010){ref-type="table"} describes the data regarding the meta-analysis of withdrawal rates in placebo-controlled RCTs studying adjunctive aripiprazole. This table has been generated with MedCalc.Table 10Data regarding the meta-analysis of withdrawal rates in placebo-controlled RCTs studying adjunctive aripiprazole.Table 10StudyInterventionControlsOdds ratio95% CIzPWeight (%)FixedRandomKelly et al., 20184/245/200,6000,137 to 262439,0739,07Chen et al., 20158/894/300,6420,179 to 230751,9951,99Shim et al., 20072/260/2858160,266 to 127,0698,948,94Total (fixed effects)14/1399/780,8410,346 to 2045−0,3820,702100,00100,00Total (random effects)14/1399/780,7610,303 to 1915−0,5790,562100,00100,00**Test for heterogeneity**Q1,8826DF2Significance level*P* = 0,3901I^2^ (inconsistency)0,00%95% CI for I^2^0,00 to 96,44

[Fig. 6](#fig0006){ref-type="fig"} represents the funnel plot (meta-analysis of withdrawal rates in placebo-controlled RCTs studying adjunctive aripiprazole). This figure has been generated with MedCalc.Fig. 6Funnel plot of the meta-analysis of withdrawal rates in placebo-controlled RCTs studying adjunctive aripiprazole.Fig 6

Experimental design, materials, and methods {#sec0002}
===========================================

We conducted a systematic review of 4 electronic bibliographic databases: PubMed, Scopus, PsycINFO and ClinicalTrials.gov. We aimed to identify clinical trials and observational studies considering four therapeutic options for lowering prolactin: switching antipsychotic treatment, adding aripiprazole, adding other dopamine agonists (e.g., cabergoline, bromocriptine), or adding metformin. The following search strategy was used: prolactin AND (switch\* OR aripiprazole OR bromocriptine OR cabergoline OR \"dopamine agonist\" OR metformin) AND (schizophrenia OR schizoaffective OR psychosis OR psychotic OR bipolar\*). Language was restricted to those articles written in English, Spanish, German or French. Studies published between January 1980 and March 2020 were considered for inclusion. The protocol was registered in PROSPERO (CRD42018103466). Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines [@bib0002] were followed.

Studies were only included if they met the following hierarchical inclusion criteria: (a) contained trials including patients with psychotic disorders (schizophrenia, schizoaffective disorder, bipolar disorder, brief psychotic disorder, delusional disorder, or psychotic disorder not otherwise specified) who had hyperprolactinaemia, (b) clinical trials and observational studies (randomized or non-randomized, controlled or uncontrolled, blinded or open-label \[the latter defined as a study where both the researchers and participants know which treatment is being administered\]) assessing the efficacy of four therapeutic options for lowering prolactin: switching antipsychotic treatment, adding aripiprazole, adding other dopamine agonists (e.g., cabergoline, bromocriptine), or adding metformin, (c) had information on prolactin levels at baseline and after follow-up that would allow the calculation of the effect size for the reduction in prolactin concentrations, (d) were published in peer-reviewed journals, (e) were written in English, French, German or Spanish, and (f) published between January 1980 and March 2020.

Exclusion criteria were as follows: (a) case reports or studies of less than 5 cases, (b) studies assessing prolactin changes in psychotic patients for whom the main reason for the therapeutic strategy was not hyperprolactinaemia (e.g., switching in treatment-resistant patients).

The main outcome for all studies included in the current systematic review was a change in prolactin levels from baseline to the last available follow-up. As a secondary outcome, we also reviewed withdrawal rates related to safety issues for each treatment strategy. These included adverse effects (physical symptoms or worsening in psychopathological symptoms including psychotic relapses) that led to stopping the treatment strategy. Withdrawal was defined as stopping the study or the assigned treatment once the study had begun; withdrawals prior to medication start were not considered.

Titles and/or abstracts of studies retrieved using the search strategy and those from additional sources were screened independently by two review authors to identify studies that met the inclusion criteria outlined above. The full text of these potentially eligible studies was retrieved and independently assessed for eligibility by two review team members. Any disagreement between them over the eligibility of particular studies was resolved through discussion with two additional reviewers.

A standardised, pre-piloted form was used to extract data from the included studies for assessment of the study quality and evidence synthesis. Two review authors extracted data independently, and discrepancies were identified and resolved through discussion (with two additional authors when necessary). Missing data were requested from study authors. For studies in which the primary condition (hyperprolactinaemia) was included along with other conditions but the outcomes were not specified for the subgroup of patients with hyperprolactinaemia, data were requested from study authors before the study was excluded. For studies that reported prolactin measures at an individual level in tables, we computed the mean and SD. If data were available as the median (interquartile range), the mean and SD were estimated as described previously [@bib0003]. In a few cases in which data were only available in figures (either as individual concentrations or aggregated with mean and standard deviation), we extracted this information from figures using the procedure explained in [Box 1](#tbl0011){ref-type="table"}.Box 1Procedure for obtaining prolactin concentrations from figures.Box 11. The PDF of the figure in the article was copied from Adobe PDF zooming by 600%. To determine the prolactin concentration of a particular value (y~n~), three positions (in mm) were determined using rules in Microsoft Publisher (zoom view set at 600%):y~max~: the maximum concentration of the prolactin scale. We annotated the y position of the Publisher y axis rule (in mm).y~0~: the minimal concentration of the prolactin scale (usually zero). We annotated the y position of the Publisher y axis rule (in mm).y~n~: the concentration of the prolactin value to be extracted (unknown). We annotated the y position of the Publisher y axis rule (in mm).2. Calculation of d1 and d2.d1= y~0~-y~max~ (in mm).d2= y~0~-y~n~ (in mm).3. We aimed to calculate a ratio that would reflect the increase in prolactin concentrations for each mm of y axis rule increase.Ratio PRL/d1= Range of prolactin concentrations (from y~0~ to y~max~)/d14. Calculation of prolactin concentration with the following formula:PRL (y~n~)= d2 x Ratio PRL/d1![](fx1.gif)

As not all studies included in our systematic review were RCTs, we estimated the effect sizes for the change in prolactin concentrations of all types of studies but only conducted a meta-analysis in RCTs that used placebo or maintaining antipsychotic treatment as comparator arms.

In order to determine the effect size in pre-post designs (all types of studies), the Hedges' g was used. This effect size measure for changes in prolactin after the therapeutic strategy was determined using an on-line calculator that allows the calculation of the effect size for paired samples tests (https://effect-size-calculator.herokuapp.com/\#paired-samples-*t*-test). Another effect size measure considered in the systematic review was confidence intervals (lower and upper limits) using Cohen\'s d. These measures were calculated using pre-post prolactin and standard deviation measures of all studies. Because the correlation between pre- and post-scores is required to impute the standard deviation within groups from the standard deviation of the difference, this correlation needs to be known. However, because these correlations are not always reported by studies, a common practice is to estimate the correlation from related studies. Therefore, if the correlation between pre- and post-treatment prolactin concentrations was available in the article, we used the known value. For other cases, we estimated the value by using 0.18, a correlation coefficient obtained from the Lu et al. study [@bib0004].

The meta-analysis for changes in prolactin concentrations (primary outcome) was performed in R with the metafor package using the Hedge\'s g estimator (Code 1). Pre-test and post-test pooled standard deviations were considered as explained by Morris [@bib0005]. A random effects statistical model was used. We evaluated the risk of bias using the Cochrane risk of bias tool and recoded RCTs into three categories regarding quality: good, fair and poor. Heterogeneity among the included studies was assessed with the I² statistic. Publication bias was explored with funnel plots. We did not use tests for funnel plot asymmetry because less than 10 studies were included in the meta-analysis [@bib0006]. A sensitivity analysis was also conducted including only placebo-controlled RCTs. We also conducted another meta-analysis exploring withdrawal from the study (secondary outcome) with MedCalc version 18.11 (MedCalc Software bvba), considering odds ratios as the summary measures.    

Code 1. R code used for the meta-analysis of 5 RCTs on the addition of aripiprazole for reducing prolactin concentrations in patients with a psychotic disorder and hyperprolactinaemia.    

library (metafor)    

\# Creating data frame for the treatment group. Prolactin concentrations are represented in the same units as they have been published. Data from the Kelly et al. 2018 study was remitted from the authors.    

datT \<- data.frame(

m_pre = *c*(89.36,2173.9,90.34,82.13,1406.64),

m_post = *c*(59.97,718.9,32.91,17.66,514.38),

sd_pre = *c*(65.76,807.9,49.79,88.64,682.46),

sd_post = *c*(55.58,291.9,28.93,36.61,427.0),

ni = *c*(24,30,89,24,56),

ri = *c*(0.18,0.18,0.18,0.18,0.18))    

\# Creating data frame for the control group. Prolactin concentrations are represented in the same units as they have been published. Data from the Kelly et al. 2018 study was remitted from the authors.    

datC \<- data.frame(

m_pre = *c*(76.86,2623.2,91.61,84.63,1493.75),

m_post = *c*(80.96,3419.9,87.72,91.35,2000.69),

sd_pre = *c*(40.94,1541.7,57.88,37.36,576.3),

sd_post = *c*(42.73,2091.8,57.24,45.10,1077.28),

ni = *c*(18,25,89,27,57),

ri = *c*(0.18,0.18,0.18,0.18,0.18))    

datT \<- escalc(measure=\"SMCR\", m1i=*m*\_post, m2i=*m*\_pre, sd1i=sd_pre, ni=ni, ri=ri, data=datT)

datC \<- escalc(measure=\"SMCR\", m1i=*m*\_post, m2i=*m*\_pre, sd1i=sd_pre, ni=ni, ri=ri, data=datC)    

dat \<- data.frame(yi = datT\$yi - datC\$yi, vi = datT\$vi + datC\$vi)    

\# Pooled (Morris).    

sd_pool \<- sqrt((with(datT, (ni-1)\*sd_pre\^2) + with(datC, (ni-1)\*sd_pre\^2)) / (datT\$ni + datC\$ni - 2))

dat \<- data.frame(yi = metafor:::.cmicalc(datT\$ni + datC\$ni - 2) \* (with(datT, m_post - m_pre) - with(datC, m_post - m_pre)) / sd_pool)

dat\$vi \<- 2\*(1-datT\$ri) \* (1/datT\$ni + 1/datC\$ni) + dat\$yi\^2 / (2\*(datT\$ni + datC\$ni))

round(dat, 2)    

\# Meta-analysis (Random Effects, Hedges g).    

meta\<-rma(yi, vi, data=dat, method=\"HE\", digits=2)    

meta

confint(meta)    

\# Forest plot.    

forest (meta)    

\# Funnel plot.    

funnel (meta,digits=1)      

Code 2. R code used for the sensitivity meta-analysis of 3 placebo-controlled RCTs on the addition of aripiprazole for reducing prolactin concentrations in patients with a psychotic disorder and hyperprolactinaemia.    

library (metafor)    

\# Sensitivity meta-analysis including only 3 placebo-controlled RCTs on aripiprazole addition.    

\# Creating data frame for the treatment group. Prolactin concentrations are represented in the same units as they have been published. Data from the Kelly et al. 2018 study was remitted from the authors.    

datT \<- data.frame(

m_pre = *c*(89.36,90.34,82.13),

m_post = *c*(59.97,32.91,17.66),

sd_pre = *c*(65.76,49.79,88.64),

sd_post = *c*(55.58,28.93,36.61),

ni = *c*(24,89,24),

ri = *c*(0.18,0.18,0.18))    

\# Creating data frame for the control group. Prolactin concentrations are represented in the same units as they have been published. Data from the Kelly et al. 2018 study was remitted from the authors.    

datC \<- data.frame(

m_pre = *c*(76.86,91.61,84.63),

m_post = *c*(80.96,87.72,91.35),

sd_pre = *c*(40.94,57.88,37.36),

sd_post = *c*(42.73,57.24,45.10),

ni = *c*(18,89,27),

ri = *c*(0.18,0.18,0.18))    

datT \<- escalc(measure=\"SMCR\", m1i=*m*\_post, m2i=*m*\_pre, sd1i=sd_pre, ni=ni, ri=ri, data=datT)

datC \<- escalc(measure=\"SMCR\", m1i=*m*\_post, m2i=*m*\_pre, sd1i=sd_pre, ni=ni, ri=ri, data=datC)    

dat \<- data.frame(yi = datT\$yi - datC\$yi, vi = datT\$vi + datC\$vi)    

\# Pooled (Morris).    

sd_pool \<- sqrt((with(datT, (ni-1)\*sd_pre\^2) + with(datC, (ni-1)\*sd_pre\^2)) / (datT\$ni + datC\$ni - 2))

dat \<- data.frame(yi = metafor:::.cmicalc(datT\$ni + datC\$ni - 2) \* (with(datT, m_post - m_pre) - with(datC, m_post - m_pre)) / sd_pool)

dat\$vi \<- 2\*(1-datT\$ri) \* (1/datT\$ni + 1/datC\$ni) + dat\$yi\^2 / (2\*(datT\$ni + datC\$ni))

round(dat, 2)    

\# Meta-analysis (Random Effects, Hedges g).    

meta\<-rma(yi, vi, data=dat, method=\"HE\", digits=2)

meta

confint(meta)    

\# Forest plot.    

forest (meta)    

\# Funnel plot.    

funnel (meta,digits=1) 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[^1]: Pages refer to the original article [@bib0001]; Abbreviations: OA= Original article; DIB= Data in Brief.[Fig. 1](#fig0001){ref-type="fig"}. Flow diagram of included studies.

[^2]: Abbreviations: SD= Standard deviation; NR= Not reported; CGI-*S*= Clinical Global Impression-Severity scale; PANSS= Positive and Negative Syndrome Scale; BPRS= Brief Psychiatric Rating Scale.

[^3]: In the study by Kinon et al. (2006), patients who were switched to olanzapine had a mean (SD) duration of previous drug therapy of 11.9 (8.4) years. However, it was not specified the duration of the last antipsychotic drug treatment.

[^4]: Abbreviations: SD= Standard deviation; NR= Not reported; CGI-*S*= Clinical Global Impression-Severity scale; PANSS= Positive and Negative Syndrome Scale; BPRS= Brief Psychiatric Rating Scale; ER= Emergency room.

[^5]: Abbreviations: SD= Standard deviation; NR= Not reported; CGI-*S*= Clinical Global Impression-Severity scale; PANSS= Positive and Negative Syndrome Scale; BPRS= Brief Psychiatric Rating Scale.

[^6]: In the study Kalkavoura et al. (2013), patients were under antipsychotic treatment for at least 5 years before the inclusion in the study. However, it was not specified the duration of the last antipsychotic drug treatment.

[^7]: Abbreviations: DSM-IV= Diagnostic and Statistical Manual of Mental Disorders -- IV edition; NR= Not reported.

[^8]: Information regarding substance use and exclusion criteria due to substance use disorders has been included in [Table 3](#tbl0003){ref-type="table"}.

[^9]: Abbreviations: DSM-IV= Diagnostic and Statistical Manual of Mental Disorders -- IV edition; NR= Not reported.

[^10]: Information regarding substance use and exclusion criteria due to substance use disorders has been included in [Table 4](#tbl0004){ref-type="table"}.

[^11]: Although no exclusion criteria for medical conditions were reported in the study, the authors specify that one patient with tuberous sclerosis was removed from the study because it could not be excluded that the tuberous sclerosis produced the prolactin elevation.

[^12]: Abbreviations: DSM-IV= Diagnostic and Statistical Manual of Mental Disorders -- IV edition; ICD-10= International Classification of Diseases -- 10th revision; NR= Not reported.

[^13]: Information regarding substance use and exclusion criteria due to substance use disorders has been included in [Table 5](#tbl0005){ref-type="table"}.

[^14]: Although no exclusion criteria for medical condition were reported in the study, the authors specify that all patients had normal hepatic, renal and thyroid function.

[^15]: As primary outcome was change in plasma concentrations of prolactin, all randomized clinical trials were considered to have a low risk of bias with respect to the outcome, as this is an objective measure unlikely to be biased even in unblinded situations.
